Hyderabad, Dec. 4 -- SAI Parenteral Limited Managing Director Anil K K on Thursday announced the company's acquisition of Australia-based Noumed Pharmaceuticals for Rs 125 crore, calling it a defining milestone in the group's global expansion strategy.
He was addressing reporters while outlining the company's five-year roadmap, international acquisitions, regulatory ambitions and the upcoming IPO.
Anil said the deal, after due diligence by KPMG, gives SAI Parenteral access to Noumed's extensive portfolio of 450 IP dossiers-gives rights to SAI for filing in global markets outside Australia and New Zealand.
"If we were to develop this many dossiers ourselves, it would take time and effort. This acquisition gives us an immediate strategic e...